These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and marketing of two new drugs, Inzirqo and Tezruly. Updated sales from Purified Cortophin Gel, Inzirqo and Tezruly could result in ANIP raising 2025 guidance for the 3rd time this year, in my view.
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why ANI (ANIP) Could Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Okay. Good Afternoon, everybody.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.
